Patents by Inventor Scott M. Whitcup

Scott M. Whitcup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Publication number: 20170216414
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9622957
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: April 18, 2017
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9572859
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: February 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
  • Publication number: 20160279143
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Application
    Filed: November 12, 2015
    Publication date: September 29, 2016
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Publication number: 20160228359
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Inventor: Scott M. Whitcup
  • Patent number: 9314425
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: April 19, 2016
    Assignee: Allergan, Inc.
    Inventor: Scott M. Whitcup
  • Publication number: 20160038396
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Application
    Filed: October 19, 2015
    Publication date: February 11, 2016
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9233071
    Abstract: Methods for treating and preventing ocular conditions by administering an compound to the vitreous chamber of a patient at risk of, or suffering from, the ocular condition.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, David A. Weber
  • Patent number: 9226931
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: January 5, 2016
    Assignee: Allergan, Inc.
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Patent number: 9216183
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: December 22, 2015
    Assignee: Allergan, Inc.
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney Edwards, Scott M. Whitcup
  • Patent number: 9161970
    Abstract: Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: October 20, 2015
    Assignee: Allergan, Inc.
    Inventors: Ahmet Tezel, Wendy M. Blanda, Patrick M. Hughes, Scott M. Whitcup, James N. Chang, Michael R. Robinson
  • Patent number: 9101550
    Abstract: The present invention is directed to compositions and methods for stimulating the growth of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to increase nail growth and thicken, strengthen and smooth the nail. The composition is also effective in strengthening and growing nails, including fingernails and toenails.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: August 11, 2015
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Rhett M. Schiffman, John G. Walt, Debbie D. Mullins, Connie M. Stucker
  • Patent number: 9089478
    Abstract: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: July 28, 2015
    Assignee: Allergen, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Robert T. Lyons, John T. Trogden
  • Patent number: 9050336
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: May 8, 2012
    Date of Patent: June 9, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Patent number: 9044477
    Abstract: Botulinum neurotoxin formulated with a hyaluronic acid carrier with increased residency time of the botulinum toxin at a subdermal location and fewer botulinum toxin induced complications or side effects.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: June 2, 2015
    Assignee: Allergan, Inc.
    Inventors: Wendy M. Blanda, Roger K. Aoki, Terrence J. Hunt, Patrick M. Hughes, James N. Chang, Scott M. Whitcup, Michael R. Robinson
  • Publication number: 20150147406
    Abstract: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 28, 2015
    Inventors: Michael R. Robinson, Wendy M. Blanda, Hui Liu, Scott M. Whitcup, Patrick M. Hughes
  • Publication number: 20150133559
    Abstract: Methods for treating and preventing ocular conditions by administering an compound to the vitreous chamber of a patient at risk of, or suffering from, the ocular condition.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 14, 2015
    Inventors: Scott M. Whitcup, David A. Weber
  • Publication number: 20150133415
    Abstract: Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 14, 2015
    Inventor: Scott M. Whitcup
  • Patent number: 8969415
    Abstract: Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 10 days and one year or longer.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, Guadalupe Ruiz, Werhner C. Orilla, Scott M. Whitcup, Devin F. Welty, Joan-En Lin, Lon T. Spada